{"id":"W3099980423","doi":"10.1182/blood-2020-143816","title":"Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Medicine; Open label; Myeloid leukemia; Internal medicine; Phases of clinical research; Oncology; Adverse effect; Clinical trial; Imatinib; Nilotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004387968,0.001049896,0.002077798,0.0005031164,0.0001250415,0.00009337699,0.000506466,0.0003082384,0.00005783767],"category_scores_gemma":[0.0004140677,0.0008602127,0.00006672027,0.001806753,0.0002288561,0.0004961139,0.0004658146,0.0009269548,0.00001398453],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006540463,"about_ca_system_score_gemma":0.002844739,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01172063,"about_ca_topic_score_gemma":0.02224503,"domain_scores_codex":[0.9932963,0.0003792522,0.002148309,0.002044822,0.0009850009,0.001146361],"domain_scores_gemma":[0.9967332,0.0004043264,0.0008363632,0.001173239,0.0001926114,0.000660282],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3437257,0.175163,0.4184027,0.001504242,0.00201147,0.005785976,0.0227168,0.0008439578,0.01240175,0.000002378326,0.0003245834,0.01711744],"study_design_scores_gemma":[0.8190449,0.0836769,0.07189722,0.00509887,0.00107541,0.00001597374,0.0005578357,0.002720382,0.01469027,4.380653e-7,0.0004206427,0.0008011854],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868635,0.001200303,0.000001964424,0.0002395716,0.00005469781,0.01091635,0.0005450238,0.00009556004,0.00008300769],"genre_scores_gemma":[0.9973628,0.0003896062,0.000262193,0.0001033498,0.000169512,0.0004284573,0.001074819,0.0001751851,0.00003410702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4753191,"threshold_uncertainty_score":0.9993849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02238647833757712,"score_gpt":0.2837266180933452,"score_spread":0.261340139755768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}